PL2117523T3 - Inhibitory aktywności AKT - Google Patents

Inhibitory aktywności AKT

Info

Publication number
PL2117523T3
PL2117523T3 PL08729249T PL08729249T PL2117523T3 PL 2117523 T3 PL2117523 T3 PL 2117523T3 PL 08729249 T PL08729249 T PL 08729249T PL 08729249 T PL08729249 T PL 08729249T PL 2117523 T3 PL2117523 T3 PL 2117523T3
Authority
PL
Poland
Prior art keywords
inhibitors
akt activity
akt
activity
Prior art date
Application number
PL08729249T
Other languages
English (en)
Inventor
Mark Andrew Seefeld
Meagan B Rouse
Dirk A Heerding
Simon Peace
Dennis S Yamashita
Kenneth C Mcnulty
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2117523(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2117523T3 publication Critical patent/PL2117523T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08729249T 2007-02-07 2008-02-07 Inhibitory aktywności AKT PL2117523T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88858607P 2007-02-07 2007-02-07
EP08729249.6A EP2117523B1 (en) 2007-02-07 2008-02-07 Inhibitors of akt activity
PCT/US2008/053269 WO2008098104A1 (en) 2007-02-07 2008-02-07 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
PL2117523T3 true PL2117523T3 (pl) 2014-11-28

Family

ID=39682107

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08729249T PL2117523T3 (pl) 2007-02-07 2008-02-07 Inhibitory aktywności AKT

Country Status (34)

Country Link
US (7) US8273782B2 (pl)
EP (1) EP2117523B1 (pl)
JP (3) JP4723677B2 (pl)
KR (3) KR101537825B1 (pl)
CN (1) CN101646427B (pl)
AR (1) AR066184A1 (pl)
AU (1) AU2008213694B2 (pl)
BR (1) BRPI0807146B8 (pl)
CA (1) CA2678255C (pl)
CL (1) CL2008000348A1 (pl)
CO (1) CO6220930A2 (pl)
CR (1) CR10995A (pl)
CY (1) CY1115535T1 (pl)
DK (1) DK2117523T3 (pl)
DO (1) DOP2009000196A (pl)
EA (1) EA018038B1 (pl)
ES (1) ES2501518T3 (pl)
HR (1) HRP20140790T1 (pl)
IL (1) IL200212A (pl)
JO (1) JO3134B1 (pl)
MA (1) MA31167B1 (pl)
MX (2) MX2009008550A (pl)
MY (1) MY164480A (pl)
NZ (1) NZ579177A (pl)
PE (1) PE20090058A1 (pl)
PL (1) PL2117523T3 (pl)
PT (1) PT2117523E (pl)
SG (1) SG193678A1 (pl)
SI (1) SI2117523T1 (pl)
TW (2) TWI507194B (pl)
UA (1) UA102992C2 (pl)
UY (1) UY30892A1 (pl)
WO (1) WO2008098104A1 (pl)
ZA (1) ZA200905363B (pl)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UA106740C2 (uk) * 2009-01-30 2014-10-10 Глаксосмітклайн Ллс Кристалічний гідрохлорид n-{(1s)-2-аміно-1-[(3-фторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1h-піразол-5-іл)-2-тіофенкарбоксаміду
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
EA201270453A1 (ru) * 2009-09-23 2013-12-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация
BR112012006693A2 (pt) * 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
BR112012008274A2 (pt) * 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
US8835450B2 (en) 2009-10-08 2014-09-16 Glaxosmithkline Llc Combination of inhibitor of B-Raf and an inhibitor of Akt in the treatment of cancer
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
WO2011146710A1 (en) 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination
US20130237554A1 (en) * 2010-05-26 2013-09-12 Rakesh Kumar Combination
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184542A1 (en) 2011-01-19 2012-07-19 Kevin Anderson Pyrido pyrimidines
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
WO2013096642A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR112014026706A2 (pt) 2012-04-24 2017-06-27 Glaxosmithkline Ip No 2 Ltd método de tratamento para dermatoses responsivas a esteroides
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
KR20150070347A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. Ror-감마-t의 메틸렌 결합 퀴놀리닐 조절제
AU2013334943A1 (en) * 2012-10-22 2015-05-14 Novartis Ag Combination
SG11201503688SA (en) 2012-11-30 2015-06-29 Glaxosmithkline Llc Novel pharmaceutical composition
CA2897559A1 (en) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combination
US10053454B2 (en) 2013-02-27 2018-08-21 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
RU2678830C2 (ru) 2013-03-15 2019-02-04 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
KR20150130405A (ko) * 2013-03-15 2015-11-23 베르선 코포레이션 트롬빈의 억제제로서의 할로게노피라졸
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
CN105792825A (zh) 2013-10-01 2016-07-20 诺华股份有限公司 组合
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CN105636952A (zh) 2013-10-15 2016-06-01 詹森药业有限公司 Rorγt的仲醇喹啉基调节剂
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
SMT201800643T1 (it) 2013-12-24 2019-01-11 Bristol Myers Squibb Co Composti triciclici come agenti anticancro
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
WO2015136398A1 (en) 2014-03-12 2015-09-17 Novartis Ag Combination comprising a btk inhibitor and an akt inhibitor
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
MA39999A (fr) 2014-06-06 2015-12-10 Res Triangle Inst Agonistes du récepteur de l'apeline (apj) et leurs utilisations
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
HK1246164A1 (zh) 2015-02-27 2018-09-07 Verseon Corporation 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN107921026A (zh) 2015-08-28 2018-04-17 诺华股份有限公司 药物组合物包含(a)α‑同种型特异性PI3K抑制剂alpelisib(BYL719)和(b)AKT抑制剂,优选MK‑2206,afuresertib或uprosertib及其在治疗/预防癌症中的应用
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
EP3386976A1 (en) 2015-12-09 2018-10-17 Research Triangle Institute, International Improved apelin receptor (apj) agonists and uses thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
KR102351270B1 (ko) * 2016-06-16 2022-01-14 하얼빈 젠바오 파마슈티컬 컴퍼니, 리미티드 Akt 억제제인 디히드로피라졸로아제핀계 화합물
RU2764039C2 (ru) * 2016-10-12 2022-01-14 Рисерч Трайэнгл Инститьют Гетероциклические агонисты рецептора апелина (apj) и их применение
JP2020510618A (ja) 2016-12-01 2020-04-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を処置する方法
EP3573619A4 (en) 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
EP3648744A1 (en) 2017-07-05 2020-05-13 Novartis AG Novel pharmaceutical composition
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
PT3725791T (pt) * 2017-12-13 2023-04-04 Harbin Zhenbao Pharmaceutical Co Ltd Sal que serve como inibidor de akt e seu cristal
WO2020023340A1 (en) 2018-07-23 2020-01-30 Signalrx Pharmaceuticals, Inc. Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof
JP2022512706A (ja) 2018-10-16 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 眼科におけるＡｋｔ阻害剤の使用
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CA3121140A1 (en) 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
CN114080225A (zh) 2019-08-08 2022-02-22 来凯有限公司 治疗癌症的方法
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
JP2023519882A (ja) 2020-03-27 2023-05-15 ソム、イノベーション、バイオテック、ソシエダッド、アノニマ シヌクレイノパチーの治療に有用な化合物
CN111620860B (zh) * 2020-06-23 2023-02-03 济南健丰化工有限公司 一种福瑞塞替的制备方法
CN111592531B (zh) * 2020-06-23 2023-08-15 上海鲲博玖瑞医药科技发展有限公司 福瑞塞替的制备方法
TW202222790A (zh) 2020-10-01 2022-06-16 德商拜耳廠股份有限公司 製備4-溴呋喃-2-羧酸酯之方法
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer
CA3255389A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
CN120051280A (zh) 2022-10-17 2025-05-27 阿斯利康(瑞典)有限公司 用于治疗癌症的serd的组合
JP2025539034A (ja) 2022-11-11 2025-12-03 アストラゼネカ・アクチエボラーグ 癌の治療のための併用療法
WO2024249875A1 (en) 2023-06-02 2024-12-05 Arvinas Operations, Inc. Combinations of estrogen receptor degraders and akt inhibitors
CN117486856A (zh) * 2023-11-02 2024-02-02 上海毕得医药科技股份有限公司 一种4-溴-5-(三氟甲基)噻吩-2-羧酸甲酯的合成方法

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
ES2005163A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
EP0333427B1 (en) 1988-03-16 1995-08-23 Smithkline Beecham Farmaceutici S.p.A. Heterocyclic derivatives
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3927483A1 (de) 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
DE3933573A1 (de) 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP3322878B2 (ja) 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
US5631269A (en) 1992-10-23 1997-05-20 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
DE69418045T2 (de) * 1993-08-06 1999-10-07 Smithkline Beecham P.L.C., Brentford Amidderivate als 5ht1d rezeptor antagonisten
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
MX9702382A (es) 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevos derivados de pirimidona con actividad antifungica.
CA2201478A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia S.A. New carboxamides with antifungal activity
EP1304322A3 (en) 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5942544A (en) 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
AU706314B2 (en) 1996-04-03 1999-06-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715606B2 (en) 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU714851B2 (en) 1996-04-03 2000-01-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0904076A1 (en) 1996-04-03 1999-03-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249645A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036901A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036881A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891333A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507591A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
AUPO163896A0 (en) 1996-08-14 1996-09-05 Resmed Limited Determination of respiratory airflow
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
US5998336A (en) 1997-02-26 1999-12-07 The Board Of Trustees Of The Leland Stanford Junior University Ceramic/metal and A15/metal superconducting composite materials exploiting the superconducting proximity effect and method of making the same
US6359134B1 (en) 1997-05-30 2002-03-19 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
DE19882893T1 (de) 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPP433398A0 (en) 1998-06-25 1998-07-16 Australian National University, The Compounds and processes
US6192967B1 (en) 1998-10-19 2001-02-27 Sunny En Liung Huang Collapsible auto shade
US6130333A (en) 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
DE19904396A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
IL145773A0 (en) 1999-04-13 2002-07-25 Basf Ag Integrin receptor ligands
EP1183235A2 (en) 1999-05-24 2002-03-06 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
AU5155500A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001038309A1 (en) 1999-11-24 2001-05-31 Cor Therapeutics, Inc. β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
BR0104424A (pt) * 2000-02-05 2002-01-08 Vertex Pharma Composições de pirazol úteis como inibidores de erk
WO2001056993A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
WO2001056557A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
WO2001087287A2 (en) 2000-05-19 2001-11-22 Applied Research Systems Ars Holding N.V. Use of pyrazole derivatives for treating infertility
US6589195B1 (en) * 2000-05-26 2003-07-08 Orthomerica Products, Inc. Modular adjustable prophylactic hip orthosis and adduction/abduction joint
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
WO2002007823A2 (en) 2000-07-24 2002-01-31 Davide Riccardo Grassetti Inhibition of mutagenic effects of carcinogens
GB0018758D0 (en) 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
WO2002064136A2 (en) 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
EP1390353A1 (en) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
DE10223912A1 (de) * 2001-06-28 2003-01-16 Merck Patent Gmbh TN- und STN-Flüssigkristallanzeigen
US20030015823A1 (en) * 2001-07-18 2003-01-23 Hydranautics Method for forming a thick section, thermoset, solid casting
CA2456192A1 (en) 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
EP1423380B1 (en) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
ATE372114T1 (de) 2001-09-27 2007-09-15 Applied Research Systems Verfahren zur erhöhung des testosteronspiegels
US6794252B2 (en) * 2001-09-28 2004-09-21 Texas Instruments Incorporated Method and system for forming dual work function gate electrodes in a semiconductor device
WO2003035619A1 (en) 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2003039529A1 (en) 2001-11-07 2003-05-15 4Sc A.G. Selective antibacterial agents
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
SG159380A1 (en) 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
US7335779B2 (en) 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
EP1494997A4 (en) 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
WO2003090751A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
JP2005529328A (ja) 2002-06-05 2005-09-29 ファーマシア アンド アップジョン カンパニー 競合的結合１ｈｎｍｒ実験を用いたリガンドの同定方法
GB0216224D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
JP2005539001A (ja) 2002-08-02 2005-12-22 アージェンタ・ディスカバリー・リミテッド ヒストンデアセチラーゼインヒビターとしての置換チエニルヒドロキサム酸
JP2006506340A (ja) 2002-08-09 2006-02-23 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体５のモジュレーターとしてのオキサジアゾール
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
EP1537099B1 (en) 2002-08-23 2010-08-11 Novartis Vaccines and Diagnostics, Inc. Pyrrole based inhibitors of glycogen synthase kinase 3
DE10239443A1 (de) 2002-08-28 2004-03-11 Boehringer Ingelheim International Gmbh Blockiervorrichtung für ein Sperrspannwerk mit federbetätigtem Abtrieb
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
JP2006514951A (ja) 2002-12-13 2006-05-18 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
CA2515235A1 (en) 2003-02-10 2004-08-19 Bayer Healthcare Ag Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
TW200512195A (en) 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
US7612064B2 (en) 2003-05-26 2009-11-03 Takeda Pharmaceutical Company Limited Sulfopyrroles
WO2004113331A1 (en) 2003-06-20 2004-12-29 Galderma Research & Development, S.N.C. Novel compounds that modulate pparϝ type receptors, and use thereof in cosmetic or pharmaceutical compositions
DE10331305A1 (de) 2003-07-10 2005-02-17 Siemens Ag Kommunikationssystem, Peer-to-Peer-Nachrichten-Filter-Rechner und Verfahren zum Verarbeiten einer Peer-to-Peer-Nachricht
FR2857666B1 (fr) 2003-07-15 2005-08-26 Oreal Composition tinctoriale comprenant a titre de coupleur un derive du furane et nouveaux derives du furane
PT1651232E (pt) 2003-07-23 2011-02-16 Synta Pharmaceuticals Corp Compostos para inflamação e utilizações imunorelacionadas
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
US20050101650A1 (en) 2003-08-15 2005-05-12 Alex Aronov Pyrrole compositions useful as inhibitors of c-Met
WO2005019182A1 (en) 2003-08-20 2005-03-03 Bayer Healthcare Ag Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists
US20070004771A1 (en) 2003-10-06 2007-01-04 Glaxo Group Limited Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors
US20070123561A1 (en) 2003-10-06 2007-05-31 Dennis Lee Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
WO2005077435A1 (en) 2004-01-19 2005-08-25 Atul Kumar A system for distending body tissue cavities by continuous flow irrigation
JP2007519753A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
CN1934836A (zh) * 2004-03-30 2007-03-21 松下电器产业株式会社 内容中继服务器、内容中继系统、内容中继方法和采用该方法的程序
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2005336172A (ja) 2004-04-26 2005-12-08 Japan Tobacco Inc 腎虚血再灌流障害治療又は予防薬
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
CA2568742A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Substituted thiazoleacetic as crth2 ligands
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
EP2325184A1 (en) * 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
US20060019968A1 (en) * 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of neuropathic pain
US7269099B2 (en) 2004-07-30 2007-09-11 Bolt Technology Corporation Air gun
JP2006066488A (ja) * 2004-08-25 2006-03-09 Mitsubishi Electric Corp 半導体受光素子およびその製造方法
US7365385B2 (en) * 2004-08-30 2008-04-29 Micron Technology, Inc. DRAM layout with vertical FETs and method of formation
US20060043513A1 (en) * 2004-09-02 2006-03-02 Deok-Hoon Kim Method of making camera module in wafer level
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20060062453A1 (en) * 2004-09-23 2006-03-23 Sharp Laboratories Of America, Inc. Color highlighting document image processing
WO2006043518A1 (ja) 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
JP2006120339A (ja) 2004-10-19 2006-05-11 Matsushita Electric Ind Co Ltd 高周波加熱電源装置
TW200619843A (en) 2004-10-20 2006-06-16 Sumitomo Bakelite Co Semiconductor wafer and semiconductor device
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP1814866A2 (en) 2004-11-23 2007-08-08 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
DE602005012722D1 (de) 2004-11-30 2009-03-26 Neurosearch As Neuartige diazabicyclische arylderivate als cholinerge liganden
SE527990C2 (sv) 2004-12-06 2006-08-01 Mora Of Sweden Ab Isborr
RU2007132973A (ru) 2005-02-03 2009-03-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов ppar
JP2006232707A (ja) 2005-02-23 2006-09-07 Japan Tobacco Inc 癌転移抑制剤
US20080207760A1 (en) 2005-04-11 2008-08-28 Achillion Pharmaceuticals, Inc. Pharmaceutical Compositions For and Methods of Inhibiting Hcv
AR056319A1 (es) 2005-04-22 2007-10-03 Kalypsys Inc Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
US20060288588A1 (en) 2005-06-22 2006-12-28 Frank Morabito Garden tool
US8541461B2 (en) * 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US20060293320A1 (en) 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
WO2006136637A2 (es) * 2005-06-24 2006-12-28 Eloy Antonio Martinez Albal Implante dental de corona rotatoria
EP1910307A1 (en) 2005-06-27 2008-04-16 Exelixis, Inc. Pyrazole based lxr modulators
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
JP2009519966A (ja) 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な６員ヘテロ環
JP2009521504A (ja) * 2005-12-22 2009-06-04 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性阻害剤
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
AU2007221020B9 (en) 2006-02-28 2013-04-04 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
JP2007277230A (ja) 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
EP2518063B1 (en) 2006-12-21 2017-02-01 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
CA2671766A1 (en) 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
US8420690B2 (en) 2007-02-07 2013-04-16 Glaxosmithkline Llc Inhibitors of Akt activity
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008121685A1 (en) 2007-03-28 2008-10-09 Smithkline Beecham Corporation Methods of use for inhibitors of akt activity
JP2010522770A (ja) 2007-03-29 2010-07-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害物質

Also Published As

Publication number Publication date
KR20140140570A (ko) 2014-12-09
PT2117523E (pt) 2014-09-29
DK2117523T3 (da) 2014-09-08
ES2501518T3 (es) 2014-10-02
MA31167B1 (fr) 2010-02-01
US8946278B2 (en) 2015-02-03
MX367398B (es) 2019-08-20
HK1132676A1 (en) 2010-03-05
US20100041726A1 (en) 2010-02-18
CY1115535T1 (el) 2017-01-04
UY30892A1 (es) 2008-09-02
UA102992C2 (en) 2013-09-10
EA018038B1 (ru) 2013-05-30
CN101646427B (zh) 2013-06-12
BRPI0807146A2 (pt) 2014-04-15
JP5511879B2 (ja) 2014-06-04
US20150152092A1 (en) 2015-06-04
JP5010038B2 (ja) 2012-08-29
TWI381836B (zh) 2013-01-11
KR101537825B1 (ko) 2015-07-22
EP2117523B1 (en) 2014-06-25
AU2008213694B2 (en) 2013-07-04
AU2008213694A1 (en) 2008-08-14
ZA200905363B (en) 2010-05-26
US20160287561A1 (en) 2016-10-06
TW200845964A (en) 2008-12-01
KR101521002B1 (ko) 2015-05-19
PE20090058A1 (es) 2009-04-03
JO3134B1 (ar) 2017-09-20
SI2117523T1 (sl) 2014-10-30
BRPI0807146B1 (pt) 2020-05-26
US20090209607A1 (en) 2009-08-20
JP2011126896A (ja) 2011-06-30
AU2008213694A2 (en) 2010-06-24
TW201130490A (en) 2011-09-16
CA2678255C (en) 2014-06-03
BRPI0807146B8 (pt) 2021-05-25
KR20120130298A (ko) 2012-11-30
EP2117523A4 (en) 2011-05-25
MX2009008550A (es) 2009-11-09
AR066184A1 (es) 2009-08-05
CR10995A (es) 2009-10-16
EP2117523A1 (en) 2009-11-18
US20110071182A1 (en) 2011-03-24
WO2008098104A1 (en) 2008-08-14
JP4723677B2 (ja) 2011-07-13
JP2010518110A (ja) 2010-05-27
US20130231378A1 (en) 2013-09-05
TWI507194B (zh) 2015-11-11
JP2012167096A (ja) 2012-09-06
EA200970738A1 (ru) 2010-06-30
KR20090110866A (ko) 2009-10-22
DOP2009000196A (es) 2009-10-31
US20100267759A1 (en) 2010-10-21
US8410158B2 (en) 2013-04-02
MY164480A (en) 2017-12-29
CN101646427A (zh) 2010-02-10
CO6220930A2 (es) 2010-11-19
SG193678A1 (en) 2013-10-30
US8273782B2 (en) 2012-09-25
WO2008098104A8 (en) 2009-07-30
HRP20140790T1 (hr) 2014-10-10
NZ579177A (en) 2012-01-12
CL2008000348A1 (es) 2008-08-18
IL200212A0 (en) 2010-04-29
CA2678255A1 (en) 2008-08-14
IL200212A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IL200212A0 (en) Inhibitors of akt activity
EP2114388A4 (en) INHIBITORS OF AKT'S ACTIVITY
IL209488A0 (en) Inhibitors of akt activity
IL190968A0 (en) Inhibitors of akt activity
EP1968568A4 (en) HEMMER OF NUTS ACTIVITY
IL187690A0 (en) Inhibitors of akt activity
LT2848610T (lt) Kinazės aktyvumo inhibitoriai
EP2303852A4 (en) ACTIVITY INHIBITORS AKT
EP2134175A4 (en) HAMMER OF ACT ACTIVITY
ZA201000318B (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
EP2306825A4 (en) HAMMER OF ACT ACTIVITY
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
EP2391623A4 (en) HAMMER OF ACT ACTIVITY
IL205043A0 (en) Inhibitors of c - fms kinase
IL220153A0 (en) Inhibitors of akt activity
EP2303277A4 (en) HAMMER OF ACT ACTIVITY
EP2303017A4 (en) HAMMER OF ACT ACTIVITY
EP2303258A4 (en) ACTIVITY INHIBITORS AKT
EP1948185A4 (en) INHIBITORS OF AKT ACTIVITY
ZA200709762B (en) Inhibitors of Akt activity
ZA200803485B (en) Inhibitors of akt activity
HK1129677A (zh) Akt活性抑制劑
GB2452842B (en) Method of increasing activity
AU2006906359A0 (en) Inhibitors of kinase activity
GB0803895D0 (en) Inhibitors of glyoxalase